• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Keros Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

    5/29/25 6:58:59 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email
    kros-20250528
    0001664710FALSE00016647102025-05-282025-05-280001664710us-gaap:CommonStockMember2025-05-282025-05-280001664710us-gaap:PreferredStockMember2025-05-282025-05-28

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM 8-K 
     
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 28, 2025
     
     
    Keros Therapeutics, Inc.
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware 001-39264 81-1173868
    (state or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (I.R.S. Employer
    Identification No.)
    1050 Waltham Street, Suite 302
    Lexington, Massachusetts
     02421
    (Address of principal executive offices) (Zip Code)
    Registrant’s telephone number, including area code: (617) 314-6297
     
    Not applicable
    (Former name or former address, if changed since last report.)
     
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
     
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 



     
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class 
    Trading
    Symbol
     
    Name of each exchange
    on which registered
    Common Stock, $0.0001 par value per share KROS The Nasdaq Stock Market LLC
    Preferred Share Purchase RightsN/AThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     



    Item 2.05 Costs Associated with Exit or Disposal Activities.

    On May 28, 2025, the Board of Directors of Keros Therapeutics, Inc. (the “Company”) formally approved a plan to reduce the Company’s overall workforce by approximately 45% (the “Reorganization”). These plans were communicated to affected employees on May 29, 2025.

    The Company expects to incur one-time cash charges associated with the Reorganization of approximately $3.2 million related to employee severance payments and related costs, which are expected to be expensed in the second quarter of 2025. In addition, the Company has committed to pay one-time employee retention costs to certain employees of up to approximately $0.4 million, which are expected to be incurred through the fourth quarter of 2025. The Company expects the Reorganization will be substantially complete by the fourth quarter of 2025.

    The estimates of the charges and expenditures that the Company expects to incur in connection with the Reorganization, and the timing thereof, are subject to several assumptions and the actual amounts incurred may differ materially from these estimates. In addition, the Company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the Reorganization.

    Item 8.01 Other Events.

    On May 29, 2025, the Company issued a press release announcing topline data from its TROPOS trial and corporate update. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference.

    A copy of the TROPOS topline results presentation is posted on the Company’s website and is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

    Cautionary Note Regarding Forward-Looking Statements

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements regarding the expecting timing for incurring costs associated with the Reorganization, the expected timing of implementing and completing the Reorganization and the Company’s plans to retain certain individuals to assist in this process. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including, but not limited to, the risk that the Company may not be able to implement the Reorganization as currently anticipated or within the timing currently anticipated, the impact of the Reorganization on the Company’s business, the risk that the Company’s cost saving initiatives may not be successful, and unanticipated charges not currently contemplated that may occur as a result of the Reorganization. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
     
    Item 9.01     Financial Statements and Exhibits.
     
    (d) Exhibits
    Exhibit  
    No. Description
    99.1
     
    Press Release dated May 29, 2025.
    99.2
    TROPOS Topline Results Presentation dated May 29, 2025
    104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    KEROS THERAPEUTICS, INC.
    By: /s/ Jasbir Seehra
     
    Jasbir Seehra, Ph.D.
    Chief Executive Officer
    Dated: May 29, 2025

    Get the next $KROS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    12/12/2024Outperform → Mkt Perform
    William Blair
    12/12/2024Buy → Neutral
    BTIG Research
    More analyst ratings

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/13/24 6:38:35 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      2/9/24 9:16:07 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

      SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

      1/26/24 5:26:51 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Keros Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

      1/21/25 7:51:46 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Keros Therapeutics from Outperform to Neutral and set a new price target of $15.00

      1/17/25 11:09:49 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Keros Therapeutics with a new price target

      Oppenheimer reiterated coverage of Keros Therapeutics with a rating of Outperform and set a new price target of $63.00 from $102.00 previously

      12/16/24 8:15:23 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

      Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced topline data from the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arte

      5/29/25 6:55:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees

      Keros Board Best Equipped to Oversee Strategic Review Process and Execute on Ultimate Outcome of that Process ADAR1's Disruptive and Self-Serving Campaign Stands to Jeopardize the Future Value Maximizing Potential of the Company Keros Urges Stockholders to Protect the Value of Their Investment by Voting "FOR" All Three of the Company's Highly Qualified Director Nominees LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros", the "Company" or "we") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling o

      5/27/25 1:45:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

      ADAR1 Urges Board to Release Strategic Review Results Before, Not After, Annual Meeting AUSTIN, Texas, May 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ("ISS") has recommended that Keros stockholders WITHHOLD votes from incumbent directors Dr. Mary Ann Gray and Dr. Alpna Seth at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 4, 2025.

      5/21/25 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    SEC Filings

    See more
    • Keros Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/29/25 6:58:59 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Keros Therapeutics Inc.

      DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/27/25 1:49:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Keros Therapeutics Inc.

      DEFA14A - Keros Therapeutics, Inc. (0001664710) (Filer)

      5/19/25 8:02:47 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Leadership Updates

    Live Leadership Updates

    See more
    • Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

      LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

      10/16/24 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors

      LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. "On behalf of the Board, we are delighted to welcome Jean-Jacques to Keros during this pivotal phase of our growth," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "Jean-Jacques is a deeply

      5/28/24 4:01:00 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors

      LEXINGTON, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it appointed Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. "Dr. Seth's deep industry experience and expertise in drug development, global operations and product launches will be an invaluable addition to our Board of Directors," said President and Chief Executive Officer Jasbir Seehra, Ph.D. "We a

      4/19/23 8:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 9:57:19 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Adar1 Capital Management, Llc claimed ownership of 4,456,706 shares (SEC Form 3)

      3 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/11/25 8:58:32 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Seehra Jasbir exercised 49,367 shares at a strike of $0.30, increasing direct ownership by 20% to 302,223 units (SEC Form 4)

      4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

      4/7/25 4:15:07 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KROS
    Financials

    Live finance-specific insights

    See more
    • Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

      LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended March 31, 2025. "In the first quarter, we reported initial topline results from the Phase 1 clinical trial of KER-065 that met key objectives and yielded valuable insights. These findings position us well as we prepare to engage with regulators with the aim

      5/6/25 4:01:42 PM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Review of Strategic Alternatives

      Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that its Board of Directors (the "Board") has determined to initiate a formal review process to evaluate strategic alternatives to maximize stockholder value for the Company. In connection with this determination, th

      4/10/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

      Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy ("DMD") and other neuromuscular indicationsKeros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interactionKeros to host a conference call and webcast today, March 31, 2025, at 8:00 a.m. ET LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic

      3/31/25 6:00:00 AM ET
      $KROS
      Biotechnology: Pharmaceutical Preparations
      Health Care